

Filed: August 3, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner,

v.

ASTRAZENECA AB

Patent Owner.

Case No. IPR2016-01316 (6,774,122)

Case No. IPR2016-01324 (7,456,160)

Case No. IPR2016-01325 (8,329,680)

Case No. IPR2016-01326 (8,466,139)¹

**UPDATED MANDATORY NOTICE PURSUANT TO
37 CFR §§ 42.8(a)(3) AND (b)(2)**

¹ A word-for-word identical Notice is being filed in each proceeding.

Pursuant to 37 C.F.R. §§ 42.8(a)(3) and 42.8(b)(2), Petitioners hereby identify the following litigation in which United States Patent Nos. 6,774,122, 7,456,160, 8,329,680, and 8,466,139 are asserted by Patent Owner:

- *AstraZeneca Pharmaceuticals LP et al. v. Mylan Institutional LLC*,
Civil Action No. 1:16-cv-04612-RMB-KMW (D.N.J.), filed July 29,
2016.

Dated: August 3, 2016

/Brandon M. White/

Brandon M. White

Reg. No. 52,354

Perkins Coie LLP

700 13th St. NW, Suite 600

Washington, D.C. 20005

Telephone: (202) 654-6206

E-mail: bmwhite@perkinscoie.com

Attorney for Mylan Pharmaceuticals Inc.

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing UPDATED MANDATORY NOTICE PURSUANT TO 37 CFR §§ 42.8(a)(3) AND (b)(2) was served electronically via email as follows:

Patent Owners:

Filko Prugo
O'Melveny & Myers LLP
fprugo@omm.com

Caitlin Hogan
O'Melveny & Myers LLP
chogan@omm.com

Marc Pensabene
O'Melveny & Myers LLP
mpensabene@omm.com

Kevin Murray
O'Melveny & Myers LLP
Kmurray2@omm.com

Dated: August 3, 2016

/Brandon M. White/
Brandon M. White

Attorney for Mylan Pharmaceuticals Inc.